Aduro BioTech (NASDAQ:ADRO) Stock Rating Upgraded by ValuEngine

Aduro BioTech (NASDAQ:ADRO) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Thursday, ValuEngine reports.

A number of other research analysts have also recently issued reports on the stock. Oppenheimer cut shares of Aduro BioTech from an “outperform” rating to a “market perform” rating in a research note on Monday, June 3rd. Leerink Swann assumed coverage on shares of Aduro BioTech in a research report on Monday, April 15th. They issued an “outperform” rating on the stock. CIBC restated a “market perform” rating on shares of Aduro BioTech in a research report on Monday, June 3rd. BidaskClub upgraded shares of Aduro BioTech from a “sell” rating to a “hold” rating in a research report on Tuesday, April 30th. Finally, Cowen restated a “buy” rating on shares of Aduro BioTech in a research report on Wednesday, May 8th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Aduro BioTech presently has an average rating of “Buy” and a consensus target price of $8.01.

NASDAQ:ADRO traded down $0.05 during mid-day trading on Thursday, reaching $1.35. The stock had a trading volume of 341,152 shares, compared to its average volume of 389,110. The business has a 50-day simple moving average of $1.57. The stock has a market capitalization of $108.05 million, a PE ratio of -1.16 and a beta of 1.48. The company has a quick ratio of 9.11, a current ratio of 9.11 and a debt-to-equity ratio of 0.29. Aduro BioTech has a 12 month low of $1.25 and a 12 month high of $8.10.

Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.05). The firm had revenue of $4.89 million during the quarter, compared to the consensus estimate of $4.56 million. Aduro BioTech had a negative net margin of 784.73% and a negative return on equity of 63.81%. Sell-side analysts expect that Aduro BioTech will post -0.92 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Swiss National Bank boosted its stake in shares of Aduro BioTech by 21.4% in the 2nd quarter. Swiss National Bank now owns 89,000 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 15,700 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Aduro BioTech by 32.0% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 239,000 shares of the biotechnology company’s stock valued at $366,000 after purchasing an additional 58,000 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Aduro BioTech by 63.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,400 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 22,700 shares in the last quarter. Metropolitan Life Insurance Co NY purchased a new stake in shares of Aduro BioTech in the 1st quarter valued at $99,000. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Aduro BioTech in the 1st quarter valued at $137,000. Hedge funds and other institutional investors own 41.76% of the company’s stock.

Aduro BioTech Company Profile

Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.

Further Reading: What is a portfolio manager?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.